BRADFORD SCHOLARS

    • Sign in
    View Item 
    •   Bradford Scholars
    • Life Sciences
    • Life Sciences Publications
    • View Item
    •   Bradford Scholars
    • Life Sciences
    • Life Sciences Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of Bradford ScholarsCommunitiesAuthorsTitlesSubjectsPublication DateThis CollectionAuthorsTitlesSubjectsPublication Date

    My Account

    Sign in

    HELP

    Bradford Scholars FAQsCopyright Fact SheetPolicies Fact SheetDeposit Terms and ConditionsDigital Preservation Policy

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Intermittent PI3Ko inhibition sustains anti-tumor immunity and curbs irAEs

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    View/Open
    eschweiler_et_al_2022 (12.87Mb)
    Download
    Publication date
    2022-05-26
    Author
    Eschweiler, S.
    Ramirez-Suastegui, C.
    Li, Y.
    King, E.
    Chudley, L.
    Thomas, J.
    Wood, O.
    von Witzleben, A.
    Jeffrey, D.
    McCann, K.
    Simon, H.
    Mondal, M.
    Wang, A.
    Dicker, M.
    Lopez-Guadamillas, E.
    Chou, T.-F.
    Dobbs, N.A.
    Essame, L.
    Acton, G.
    Kelly, F.
    Halbert, G.
    Sacco, J.J.
    Schache, A.G.
    Shaw, R.
    McCaul, J.A.
    Paterson, C.
    Davies, J.H.
    Brennan, Peter A.
    Singh, R.P.
    Loadman, Paul M.
    Wilson, W.
    Hackshaw, A.
    Seumois, G.
    Okkenhaug, K.
    Thomas, G.J.
    Jones, T.M.
    Ay, F.
    Friberg, G.
    Kronenberg, M.
    Vanhaesebroeck, B.
    Vijayananad, P.
    Ottensmeier, C.H.
    Show allShow less
    Keyword
    PI3Kδ inhibition
    AMG319
    Head and neck surgery
    Immunotherapy
    Research Development Fund Publication Prize Award
    Rights
    (c) 2022 The Authors. This is an Open Access article distributed under the Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/)
    Peer-Reviewed
    Yes
    Open Access status
    openAccess
    
    Metadata
    Show full item record
    Abstract
    Phosphoinositide 3-kinase δ (PI3Kδ) has a key role in lymphocytes, and inhibitors that target this PI3K have been approved for treatment of B cell malignancies1–3. Although studies in mouse models of solid tumours have demonstrated that PI3Kδ inhibitors (PI3Kδi) can induce anti-tumour immunity4,5, its effect on solid tumours in humans remains unclear. Here we assessed the effects of the PI3Kδi AMG319 in human patients with head and neck cancer in a neoadjuvant, double-blind, placebo-controlled randomized phase II trial (EudraCT no. 2014-004388-20). PI3Kδ inhibition decreased the number of tumour-infiltrating regulatory T (Treg) cells and enhanced the cytotoxic potential of tumour-infiltrating T cells. At the tested doses of AMG319, immune-related adverse events (irAEs) required treatment to be discontinued in 12 out of 21 of patients treated with AMG319, suggestive of systemic effects on Treg cells. Accordingly, in mouse models, PI3Kδi decreased the number of Treg cells systemically and caused colitis. Single-cell RNA-sequencing analysis revealed a PI3Kδi-driven loss of tissue-resident colonic ST2 Treg cells, accompanied by expansion of pathogenic T helper 17 (TH17) and type 17 CD8+ T (TC17) cells, which probably contributed to toxicity; this points towards a specific mode of action for the emergence of irAEs. A modified treatment regimen with intermittent dosing of PI3Kδi in mouse models led to a significant decrease in tumour growth without inducing pathogenic T cells in colonic tissue, indicating that alternative dosing regimens might limit toxicity.
    URI
    http://hdl.handle.net/10454/18980
    Version
    Published version
    Citation
    Eschweiler S, Ramírez-Suástegui C, Li Y et al (2022) Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs. Nature. 605: 741-746.
    Link to publisher’s version
    https://doi.org/10.1038/s41586-022-04685-2-2
    Type
    Article
    Notes
    Research Development Fund Publication Prize Award winner, May 2022.
    Collections
    Life Sciences Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.